201 related articles for article (PubMed ID: 16482461)
21. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
22. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
23. Developing Health Technology Assessment to address health care system needs.
Velasco Garrido M; Gerhardus A; Røttingen JA; Busse R
Health Policy; 2010 Mar; 94(3):196-202. PubMed ID: 19889471
[TBL] [Abstract][Full Text] [Related]
24. Health Technology Assessments in Radiology in Germany: Lack of Demand, Lack of Supply.
Winkelmann C; Neumann T; Zeidler J; Prenzler A; Vogt B; Wacker FK
Rofo; 2019 Jul; 191(7):635-642. PubMed ID: 30763963
[TBL] [Abstract][Full Text] [Related]
25. The Role of Noncomparative Evidence in Health Technology Assessment Decisions.
Griffiths EA; Macaulay R; Vadlamudi NK; Uddin J; Samuels ER
Value Health; 2017 Dec; 20(10):1245-1251. PubMed ID: 29241883
[TBL] [Abstract][Full Text] [Related]
26. [Comments by the Working Group for Methods of Economic Evaluation in Health Care (AG MEG) to IQWiG's Draft Guidelines "Methods for Assessment of the Relation of Benefits to Costs in the German Statutory Health Care System"].
Krauth C; John J; Aidelsburger P; Brüggenjürgen B; Hansmeier T; Hessel F; Kohlmann T; Moock J; Rothgang H; Schweikert B; Seitz R; Wasem J;
Gesundheitswesen; 2008 Jun; 70(6):e1-16. PubMed ID: 18661452
[TBL] [Abstract][Full Text] [Related]
27. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
[TBL] [Abstract][Full Text] [Related]
28. A comparative study of drug listing recommendations and the decision-making process in Australia, the Netherlands, Sweden, and the UK.
Salas-Vega S; Bertling A; Mossialos E
Health Policy; 2016 Oct; 120(10):1104-1114. PubMed ID: 27665497
[TBL] [Abstract][Full Text] [Related]
29. Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia.
Fischer KE; Heisser T; Stargardt T
Health Policy; 2016 Oct; 120(10):1115-1122. PubMed ID: 27628196
[TBL] [Abstract][Full Text] [Related]
30. Health technology assessment.
Hailey D
Singapore Med J; 2006 Mar; 47(3):187-92; quiz 193. PubMed ID: 16518551
[TBL] [Abstract][Full Text] [Related]
31. Development of archetypes for non-ranking classification and comparison of European National Health Technology Assessment systems.
Allen N; Pichler F; Wang T; Patel S; Salek S
Health Policy; 2013 Dec; 113(3):305-12. PubMed ID: 24176288
[TBL] [Abstract][Full Text] [Related]
32. Methods for determining cost-benefit ratios for pharmaceuticals in Germany.
von der Schulenburg J; Vauth C; Mittendorf T; Greiner W
Eur J Health Econ; 2007 Sep; 8 Suppl 1():S5-31. PubMed ID: 17582539
[TBL] [Abstract][Full Text] [Related]
33. Does conditional approval for new oncology drugs in Europe lead to differences in health technology assessment decisions?
Lipska I; Hoekman J; McAuslane N; Leufkens HG; Hövels AM
Clin Pharmacol Ther; 2015 Nov; 98(5):489-91. PubMed ID: 26250656
[TBL] [Abstract][Full Text] [Related]
34. [Quality of health care, accreditation, and health technology assessment in Croatia: role of agency for quality and accreditation in health].
Mittermayer R; Huić M; Mestrović J
Acta Med Croatica; 2010 Dec; 64(5):425-34. PubMed ID: 21692267
[TBL] [Abstract][Full Text] [Related]
35. HTA and its legal issues: a framework for identifying legal issues in health technology assessment.
Widrig D; Tag B
Int J Technol Assess Health Care; 2014 Dec; 30(6):587-94. PubMed ID: 25816824
[TBL] [Abstract][Full Text] [Related]
36. [Forecasting medical technologies--a global overview].
Tal O
Harefuah; 2011 Feb; 150(2):185-9, 202. PubMed ID: 22164951
[TBL] [Abstract][Full Text] [Related]
37. The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries.
Oortwijn W; Mathijssen J; Banta D
Health Policy; 2010 May; 95(2-3):174-84. PubMed ID: 20074829
[TBL] [Abstract][Full Text] [Related]
38. Social values and health priority setting in Germany.
Kieslich K
J Health Organ Manag; 2012; 26(3):374-83. PubMed ID: 22852459
[TBL] [Abstract][Full Text] [Related]
39. [How can the impact of Health Technology Assessment (HTA) in the Austrian healthcare system be assessed? Design of a conceptual framework].
Schumacher I; Zechmeister I
Gesundheitswesen; 2012 Apr; 74(4):257-65. PubMed ID: 21267815
[TBL] [Abstract][Full Text] [Related]
40. Using health technology assessment to support evidence-based decision-making in Canada: an academic perspective.
Xie F; Bowen JM; Sutherland SC; Burke N; Blackhouse G; Tarride JE; O'Reilly D; Goeree R
Expert Rev Pharmacoecon Outcomes Res; 2011 Oct; 11(5):513-21. PubMed ID: 21958096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
